Katy Beckermann, Medical Director of GU Clinical Research at Tennessee Oncology, shared a post on X:
“23 RCTs, 18,689 patients: no mHSPC triplet improves OS or PFS over ADT+ARPI in all-comers.
- High-volume: docetaxel triplet benefit holds (HR 0.76)
- Caveat: most controls were ADT+docetaxel, not ARPI
- Safety not stat diff for severe AE
Why it matters: Volume selects benefit. Biomarkers are next.
Who are you intensifying therapy for?”
Title: First-Line Systemic Treatments for Metastatic Hormone-Sensitive Prostate Cancer: Updated Systematic Review and Network Meta-analysis
Authors: Keiichiro Miyajima, Marcin Miszczyk, Akihiro Matsukawa, Navid Roessler, Shota Inoue, Fumihiko Urabe, Keiichiro Mori, Takafumi Yanagisawa, Pierre I. Karakiewicz, Neeraj Agarwal, Alberto Briganti, Takahiro Kimura, Shahrokh F. Shariat
Other articles featuring Katy Beckermann on OncoDaily.
